A5085620004- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Gastrointestinal disorders and treatments
- Gallbladder and Bile Duct Disorders
- Cancer Mechanisms and Therapy
- Genetic factors in colorectal cancer
- Pediatric Hepatobiliary Diseases and Treatments
- IgG4-Related and Inflammatory Diseases
- Cancer Cells and Metastasis
- Gastrointestinal Tumor Research and Treatment
- Peptidase Inhibition and Analysis
- Marine and environmental studies
- Sarcoma Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Colorectal Cancer Screening and Detection
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2014-2025
Cornell University
2020-2024
King's College Hospital
2012-2024
Johns Hopkins University
2005-2022
Vanderbilt University Medical Center
2022
Johns Hopkins Medicine
2022
The University of Texas MD Anderson Cancer Center
2021
Wayne State University
2004-2020
Emory University
2008-2020
International experts met to discuss recent advances and revise the 2004 recommendations for assessing reporting precursor lesions invasive carcinomas of pancreas, including pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), cystic neoplasm, other lesions. Consensus include following: (1) To improve concordance align with practical consequences, a 2-tiered system (low vs. high grade) is proposed all lesions, provision that current PanIN-2 neoplasms...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here a phase I trial adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA real time from surgically resected PDAC tumours. After surgery, sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), cevumeran (a maximum 20 per patient) and...
Although general characteristics of intraductal papillary mucinous neoplasms (IPMNs) and their delineation from other pancreatic tumors have been well established, several issues regarding biology management remain unresolved. It has noted briefly by us authors that there are different types papillae in IPMNs; however, frequency, biologic significance, clinical relevance unknown. In this study, the association patterns with clinical, pathologic, parameters was studied 74 IPMNs, expression...
The 2010 World Health Organization (WHO) classification recommends that pancreatic neuroendocrine tumors (PanNETs) be graded on the basis of mitotic rate and Ki67 index, with grade 2 (G2) PanNETs defined as having a to 20 figures/10 high-power fields or index 3% 20%. Grade 3 (G3) carcinoma (NEC) is >20 >20%. However, some show discordance between usually in G3 range but suggesting G2, prompting us examine clinical significance large series clinically well-characterized G2 PanNETs. Mitotic...
Objective: The aim of this study was to evaluate and validate the proposed 8th edition American Joint Committee on Cancer (AJCC) system for T N staging pancreatic adenocarcinoma. Summary Background Data: Investigators have questioned clinical relevance reproducibility previous AJCC Methods: Prospective databases at Memorial Sloan Kettering (MSK), Massachusetts General Hospital (MGH), Johns Hopkins (JHH) were queried patients who had undergone resection Patients underwent a margin-negative...
High-grade neuroendocrine neoplasms (World Health Organization [WHO] G3) of the pancreas include both well-differentiated tumor (WD-NET) and poorly differentiated carcinoma (PD-NEC). According to WHO classification scheme, diagnosis this group tumors is based on histopathology assessment proliferation fraction. However, former can be challenging due lack well-defined histologic criteria, latter alone (ie, >20 mitoses/10 high-power fields or Ki67>20%) may not sufficiently distinguish...
Most well-differentiated neuroendocrine tumors (WD-NET) of the enteropancreatic system are low-intermediate grade (G1, G2). Elevated proliferation demonstrated by either a brisk mitotic rate (>20/10 high power fields) or Ki-67 index (>20%) defines group aggressive neoplasms designated as high-grade (G3) carcinoma (NEC). High-grade NEC is equated with poorly differentiated (PD-NEC) and associated dismal outcome. Progression WD-NETs to neoplasm very rarely occurs their clinicopathologic...
There are no established guidelines for pathologic diagnosis/reporting of intraductal papillary mucinous neoplasms (IPMNs).
In the pancreas, poorly differentiated neuroendocrine carcinomas include small cell carcinoma and large are rare; data regarding their pathologic clinical features very limited.
The literature on the clinicopathologic characteristics of tumoral intraepithelial neoplasms (neoplastic polyps) gallbladder (GB) is fairly limited, due in part to variability definition and terminology. Most reported adenomas (pyloric gland type others) were microscopic thus regarded as clinically inconsequential, whereas papillary situ carcinomas have been largely considered a invasive adenocarcinoma under heading "papillary adenocarcinomas." In this study, 123 GB cases that well-defined...
Purpose: Molecular profiling in cancer has identified potential actionable drug targets that have prompted attempts to discover clinically validated biomarkers guide therapeutic decision-making and enrollment clinical trials. We evaluated whether comprehensive genetic analysis of patients with pancreatic adenocarcinoma is feasible within a relevant timeframe such analyses provide predictive and/or prognostic information along identification for therapy.Experimental Design: Archival or...
Pancreatic and colorectal cancers are often KRAS mutated incurable when tumor DNA or protein persists recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node delivery immune response using amphiphile (Amph) modification of G12D G12R mutant (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909). We treated 25 patients (20 pancreatic five colorectal) who were positive for minimal residual mKRAS disease (ctDNA and/or serum...
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present advanced disease and treated cytotoxic therapy. Genomic biomarkers prognostic of outcomes have been challenging to identify. Herein leveraging a cohort 2,336 spanning stages, we characterize the genomic clinical correlates in PDAC. We show that subtype wild-type tumors is associated early onset, distinct somatic germline features, significantly better overall...
Abstract Context.—Cystic lesions of the pancreas are being recognized with increasing frequency and have become a more common finding in clinical practice because widespread use advanced imaging modalities sharp drop mortality rate pancreatic surgery. Consequently, past 2 decades, nature many cystic tumors this organ has been better characterized, significant developments taken place classification our understanding lesions. Objective.—To provide an overview current concepts classification,...
The interaction between tumor cells and inflammatory has an important role in cancer initiation progression; however, this not been systematically investigated pancreatic neoplasia. In study, the presence of tumor-infiltrating neutrophils within and/or adjacent to neoplastic was neoplasms. Areas with >10 neutrophils/100 epithelial were arbitrarily classified as positive. Those 11–15 considered 'borderline' while those >15 'significant'. Among 363 invasive ductal carcinomas, 15 showed...